- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02652169
PRF With Topical Antibiotics or Antiseptics in Chronical Wounds Version 1.4 (PRF-TAT)
Platelet Rich Fibrin in Combination With Topical Antibiotics or Antiseptics in the Treatment of Chronic Wounds - a Prospective, Randomized, Active Controlled, Double Blind Pilot Trial With an Observer-blinded Control Group
Platelet rich fibrin (PRF) is a new therapy option for chronic wounds with yet unproven therapeutic efficacy. This randomised controlled trial aims to provide evidence of the efficacy of PRF as monotherapy as well as a growth promoting carrier matrix for antimicrobial compounds. The investigators therefore designed a four armed trial with three PRF arms which are compared to each other as well as to an active comparator. The treatment arms are as follows:
Study arm 1: PRF with amikacin and teicoplanin Study arm 2: PRF with placebo (0.9% sodium chloride) Study arm 3: PRF with PHMB (polyhexanid) plus Macrogolol (Lavasorb®) Study arm 4: Acticoat 7® wound dressing as active control Patients with infected chronic wounds may be included in this trial. Infection shall be diagnosed by an experienced senior infectious diseases specialist. Patients with untreated peripheral vascular occlusive disease as defined by an ABI (ancle brachial index) of < 0,7 are excluded from the trial as are patients with an uncontrolled diabetes mellitus or patients who have not received sufficient treatment for a diabetic foot syndrome. Any underlying illness will be treated following standard of care. In case of chronic venous insufficiency four-layered compression bandages will be applied each visit if tolerated by the patient. Alternatively compression stockings (Class III) are permitted. This is mentioned as "Disease specific treatment" in the protocol.
Patients will receive treatment for 56 days. After 28 and 56 days the wound surface will be compared to the baseline. Infection parameters (c-reactive protein and leucocyte count) will be measured weekly. Evaluation of systemic antimicrobial therapy will be performed at each visit. Systemic antimicrobial therapy is started at the discretion of a senior infectious diseases specialist.
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Florian Thalhammer, Prof. Dr.
- Phone Number: 44400 0043140400
Study Locations
-
-
-
Vienna, Austria, 1190
- Recruiting
- Medical University of Vienna
-
Contact:
- Florian Thalhammer, Prof. MD
- Phone Number: 4440 0043140400
- Email: florian.thalhammer@meduniwien.ac.at
-
Principal Investigator:
- Florian Thalhammer, Prof. MD
-
Sub-Investigator:
- Daniela A Knafl, Dr.
-
Sub-Investigator:
- Matthias G Vossen, Dr.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males and females aged over 18 who are able to give informed consent
Chronic venous ulcer with localized non-systemic soft-tissue infection diagnosed by senior infectious diseases specialist based on US FDA Guidance for Industry Chronic cutaneous ulcer and burn wounds June 2006:
- slough and necrotic tissue
- exsudate
- smell
- inflammation
- presence of granulation tissue
- pain
- Wound size ≥ 5 cm2 and < 200 cm2
Exclusion Criteria:
- Non-treated diabetes mellitus, HbA1c > 12 mg/dl
- Non treated (orthopaedic shoe) diabetic foot syndrome
- ABI < 0,7
- Wound size 15 cm2 and > 200 cm2
- CRP > 5 mg/dl
- Leucocytes > 15.000 /μl
- Infection of another site
- Infection of the ulcer with a pathogen with inherent resistance to amikacin and teicoplanin
- Known osteomyelitis
- Known erysipelas
- Known phlegmon
- Complicated deep tissue infection not solely treatable with PRF plus antimicrobial therapy in the opinion of a senior infectious diseases specialist
- Planned systemic antimicrobial therapy
- Active viral hepatitis (A/B/C) or active HIV infection or active syphilis
- Increased sensitivity to amikacin or teicoplanin, PHMB or macrogolol
- Increased sensitivity to tramexanic acid or batroxobin
- Presence of neoplastic growth in the ulcer
- Thrombocytopenic patients (<150.000 G/L)
- Haemoglobin < 95 g/L
- Known pregnancy or lactation
- Severe renal impairment (creatinine clearance <30 ml/min)
- History or clinical signs of impairment of the cochlea or vestibularis system
- Neuromuscular diseases (i.e. Myasthenia gravis, Parkinson's disease)
- Aminoglycoside treatment less than four weeks before inclusion
- Other reasons opposing the study participation on the discretion of the investigators
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Study arm 1 - PRF plus amikacin and teicoplanin
PRF mixed with amikacin and teicoplanin is sprayed on the patients' ulcer
|
PRF, mixed with amikacin and teicoplanin is applied to the chronic ulcer
Other Names:
|
Experimental: Study arm 2 - PRF plus normal saline
PRF mixed with normal saline is sprayed on the patients' ulcer
|
PRF as a monosubstance plus sodium chloride 0.9% is applied to the chronic ulcer
Other Names:
|
Experimental: Study arm 3 - PRF mixed with PHMB plus Macrogolol
PRF mixed with polyhexanide and macrogolol is sprayed on the patients' ulcer
|
PRF, mixed with Lavasorb is applied to the chronic ulcer
Other Names:
|
Active Comparator: Study arm 4 - Acticoat 7
A silver gauze (Acticoat 7®) is applied to the patients' ulcer
|
Acticoat 7 silver wound dressing is applied to the chronic ulcer
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
reduction in wound area
Time Frame: day 56
|
day 56
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of patients in necessity to initiate systemic antimicrobial therapy based on the opinion of a senior infectious disease consultant arises (subjective assessment based on wound inflammation, serum c-reactive protein levels and leucocyte count)
Time Frame: day 0, 7, 14, 21, 28, 35, 42, 49, 56
|
day 0, 7, 14, 21, 28, 35, 42, 49, 56
|
Elevation of C-reactive protein over 7 mg/dl (normal value 0.5 mg/dl)
Time Frame: day 0, 7, 14, 21, 28, 35, 42, 49, 56
|
day 0, 7, 14, 21, 28, 35, 42, 49, 56
|
time to sterility of the wound
Time Frame: day 0, 7, 14, 21, 28, 35, 42, 49, 56
|
day 0, 7, 14, 21, 28, 35, 42, 49, 56
|
Relative wound volume and wound area reduction
Time Frame: on day 28 and 56
|
on day 28 and 56
|
Occurrence of drug resistant bacteria in the wound
Time Frame: day 0, 7, 14, 21, 28, 35, 42, 49, 56
|
day 0, 7, 14, 21, 28, 35, 42, 49, 56
|
Occurrence of drug resistant bacteria in a swab of the tissue surrounding the wound or a Z-swab of the torso
Time Frame: on day 28 and 56
|
on day 28 and 56
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Florian Thalhammer, Prof. Dr., Medical University of Vienna
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRF-TAT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Skin Ulcer
-
Zagazig UniversityCompletedUlcer Foot | Chronic Skin Ulcer | Non-Healing Ulcer of SkinEgypt
-
Venenklinik BellevueCompleted
-
ACR Biologics, LLCTerminatedPressure Ulcer | Skin Ulcer Venous Stasis Chronic | Foot Ulcer ChronicUnited States
-
University Hospital, GhentJohnson & Johnson; MedtronicCompletedChronic Lower Leg UlcerBelgium
-
Noha Mohsen OmarMenoufia UniversityCompletedChronic Ulcer of Leg or Foot | Chronic Venous Hypertension With Ulcer and Inflammation
-
Loma Linda UniversityNitric BioTherapeutics, IncTerminatedChronic Ulcer of Lower ExtremityUnited States
-
Texas Health ResourcesCelleration, Inc.CompletedChronic Ulcer of Lower ExtremityUnited States
-
Amnio Technology, LLCActive, not recruitingChronic Ulcer of Lower ExtremityUnited States
-
ColdplasmatechGerman Federal Ministry of Education and ResearchRecruitingChronic Ulcer of Lower ExtremityGermany
-
Fisher and Paykel HealthcareRecruiting
Clinical Trials on PRF mixed with amikacin and teicoplanin
-
British University In EgyptCompletedMaxillary Diseases
-
Cairo UniversityRecruitingVital Pulp Treatment in Mature Permanent Teeth With Irreversible PulpitisEgypt
-
Future University in EgyptCompleted
-
Assistance Publique Hopitaux De MarseilleUnknown
-
Assistance Publique - Hôpitaux de ParisCompletedVentilator Associated PneumoniaFrance
-
University of ReadingRecruiting
-
University of California, San FranciscoWithdrawn
-
Universitaire Ziekenhuizen KU LeuvenCompletedEndodontic InflammationBelgium
-
Hams Hamed AbdelrahmanRecruiting